Latest Conference Coverage

Howard Fillit, MD: Emphasizing Care in Alzheimer Disease

With a heavy focus on the need for new treatments in Alzheimer, there remains a need to ensure patients are cared for first and foremost.

Biomarker Research Required to Further Advance Alzheimer Drug Discovery

Novel biomarkers are being explored to help expedite the development of new treatments for Alzheimer disease.

Ronald Crystal, MD: Introducing Genetics into Alzheimer Disease

Could the introduction of gene therapies into the Alzheimer space be the beginning of a new era of treatment?

Eugenia Trushina, PhD: Mitochondria as a Therapeutic Target for Alzheimer

The associate professor of neurology at Mayo Clinic spoke about targeting mitochondria to treat neurologic disorders.

Howard Fillit, MD: Alzheimer Disease Drug Development Improvement

The ADDF's founding executive director and chief scientific officer spoke about the gains in clinical trials in the last 5 years.

Allogeneic Mesenchymal Stem Cells Under Exploration for Alzheimer Disease, Aging Frailty

Allogeneic mesenchymal stem cells manufactured by Longeveron are advancing through phase I and II clinical trials.

Ronald Crystal, MD: APOE2 Gene Therapy for Alzheimer Disease

The chairman of the Department of Genetic Medicine at Weill Cornell Medicine shared his experience with the therapy and its potential in the space.

Kelvin Tsoi, PhD: Combination Therapy, Monotherapy in Alzheimer Disease

After identifying and reviewing 76 randomized trials, combination therapy with memantine and AChEIs is confirmed to have no additional benefits over monotherapy.

Lutz Frolich, MD, PhD: Learning from Negative Trials

Lutz Frölich, MD, PhD, spoke about the importance of continuing with research in light of negative trials in Alzheimer disease.

James Hendrix, PhD: Progress and Challenges in the Alzheimer Space

Hendrix spoke to the challenges he and colleagues come across, as well as his hope for the promising future.

Dennis Selkoe, MD: Current Challenges in Alzheimer Disease and Hope for the Future

Selkoe spoke to a number of topics in the Alzheimer space, including the challenges in the field and his excitement for the future.

Lutz Frolich, MD, PhD: Collaboration Between Clinicians and Industry

Lutz Frölich, MD, PhD, discussed the imperativeness of collaboration between stakeholders—clinicians, pharmaceutical companies, researchers—in developing therapies for Alzheimer disease.

Nir Lipsman, MD, PhD: Innovations in Alzheimer Disease

The neurosurgeon from Sunnybrook Health Sciences Centre spoke about his excitement about where the medical community is at, at this point, in the understanding of Alzheimer disease.

Gill Livingston, MBChB, MD: Challenges of Sleep Difficulties in People Living with Dementia

Livingston spoke to a number of topics in the dementia space, including the challenges clinicians face and her hope for the future.

Lutz Frolich, MD, PhD: Tempering Expectations for Alzheimer Disease Advancements

The head of the Department for Geriatric Psychiatry, Central Institute of Mental Health talked about the biggest challenges facing medicine in treating and understanding Alzheimer disease.

Gill Livingston, MBChB, MD: Manual Based Intervention for Sleep Difficulties in Dementia

DREAMS-START demonstrates that a manual-based psychological treatment for sleep disorders in dementia is feasible and acceptable.

Krista Lanctot, PhD: Treating Agitation in Alzheimer Disease

Nabilone significantly improved agitation, neuropsychiatric symptoms, cognition and nutrition in patients with moderate-to-severe Alzheimer disease.

John Didsbury, PhD: Going Against the Grain in Established Alzheimer

The founder and CEO of T3D Therapeutics, Inc., spoke about T3D’s desire to go against the grain and trend in the therapeutic development for mild to moderate Alzheimer disease.

Jeff D. Williamson on the SPRINT MIND Trial

The findings suggest that intensive lowering of blood pressure may reduce the risk of mild cognitive impairment and the combined risk of mild cognitive impairment and dementia, but not dementia alone.

Lutz Frolich, MD, PhD: Target Patient Populations for Alzheimer Therapies

The head of the Department for Geriatric Psychiatry, Central Institute of Mental Health discussed his thoughts about patients with mild dementia and prodromal Alzheimer disease.

Geoff Kerchner, MD, PhD: Phase III Trials of Crenezumab in Treatment of Prodromal to Mild Alzheimer

Data back a 4-fold higher dose of crenezumab in the CREAD 1 and CREAD 2 trials than used in phase II.

Harald Hampel, MD, PhD, MA, MSc on Advancements and Challenges in the Alzheimer Space

Hampel looks to the future of the Alzheimer space and sees promise, especially since there’s transfertilization from other advanced science fields in medicine like oncology, diabetes research and rheumatology.

Samantha Budd Haeberlein, PhD: The TANGO II Trial of BIIB092

The vice president and head of Alzheimer’s Disease, Dementia, and Movement Disorders in Late Stage Clinical Development at Biogen spoke about the upcoming TANGO II trial in Alzheimer disease.

Davangere Devanand, MBBS, MD: Challenges in Symptom Management in Alzheimer Disease

Davangere P. Devanand, MBBS, MD, discussed the possibility of neurologists prescribing low-dose lithium for patients with Alzheimer and symptoms of agitation.

Anton P. Porsteinsson, MD: The s-CitAD Study Design

The Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program discussed the ongoing study, which is exploring s-citalopram in patients with Alzheimer who also have symptoms of agitation.

John Didsbury, PhD: Phase IIa Trial of T3D-959 in Mild to Moderate Alzheimer Disease

Study results suggest that agonist stimulation of PPAR delta may be an effective therapeutic strategy to addressing dysfunctional metabolism in Alzheimer disease.

Samantha Budd Haeberlien, PhD: Progress in Alzheimer Drug Development

Haeberlein spoke about a number of topics in the Alzheimer space, including the progress that has been made and her excitement for the future.

Harald Hampel, MD, PhD, MA, MSc: Phase IIa Study of ANAVEX 2-73 in Treatment of Alzheimer Disease

The phase IIb/III study is scheduled to initiate enrollment of approximately 450 patients, randomized 1:1:1 to 2 different ANAVEX 2-73 doses or placebo.

Davangere Devanand, MBBS, MD: Lithium for Agitation in Alzheimer Disease

The professor of psychiatry in neurology at the Gertrude H. Sergievsky Center at Columbia University Medical Center spoke about the possibility of using lithium for agitation in Alzheimer.

Geoff Kerchner, MD, PhD: Gantenerumab as Disease-Modifying Treatment in Early Alzheimer Disease

Higher doses of gantenerumab, a monoclonal antibody designed to bind to aggregated Aβ and remove beta plaques, will be investigated in phase III trials.